Literature DB >> 31445731

A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.

Xiaodong Fei1, Liqun Zhu1, Hongxuan Zhou1, Chuang Qi2, Chun Wang3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31445731     DOI: 10.1016/j.jtho.2019.04.012

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis.

Authors:  Wanwan Cheng; Chunfa Qian; Haitao Zhang; Qi Meng; Jiani C Yin; Shencun Fang
Journal:  Anticancer Drugs       Date:  2022-08-09       Impact factor: 2.389

2.  Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes.

Authors:  Y Yao; Z Yu; Y Ma; Q Ou; X Wu; D Lu; X Li
Journal:  ESMO Open       Date:  2022-03-16

3.  A novel fusion between CDC42BPB and ALK in a patient with quadruple wild-type gastrointestinal stromal tumor.

Authors:  Wen Huang; Wei Yuan; Lei Ren; Chen Xu; Rongkui Luo; Yuhong Zhou; Weiqi Lu; Qing Hao; Mian Xu; Yingyong Hou
Journal:  Mol Genet Genomic Med       Date:  2022-03-23       Impact factor: 2.473

4.  Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.

Authors:  Huanling Xia; Binbin Liang; Guoxiang Liu; Yingxue Qi; Ningning Luo; Mengmeng Li
Journal:  Medicine (Baltimore)       Date:  2022-04-08       Impact factor: 1.817

5.  Identification of Genes Associated with the Metastasis of Pheochromocytoma/Paraganglioma Based on Weighted Gene Coexpression Network Analysis.

Authors:  Qisheng Su; Qinpei Ding; Zunni Zhang; Zheng Yang; Yuling Qiu; Xiaohong Li; Wuning Mo
Journal:  Biomed Res Int       Date:  2020-02-05       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.